OPEN ACCESS

Original research

Continuous electrocardiography for detecting atrial fibrillation beyond 1 year after stroke in primary care

Louise Feldborg Lyckhage ¹, Morten Lock Hansen,^{2,3} Jens Christian Toft,⁴ Susanne Lis Larsen,⁵ Bente Brendorp,⁶ Ari Mohammad Ali,¹ Troels Wienecke^{1,7}

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/heartjnl-2020-316904>).

¹Department of Neurology, Zealand University Hospital, Roskilde, Denmark

²Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark

³The Cardiovascular Research Centre, Copenhagen University Hospital, Gentofte, Denmark

⁴Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Denmark

⁵Borup and Viby General Practice, General practice in Region Zealand, Borup, Denmark

⁶Department of Cardiology, North Zealand Hospital, Hilleroed, Denmark

⁷Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Correspondence to

Dr Louise Feldborg Lyckhage and Dr Louise Feldborg Lyckhage, Neurology, Zealand University Hospital Roskilde, 4000 Roskilde, Denmark; llyckhage@hotmail.com, llyckhage@hotmail.com

Received 15 March 2020

Revised 16 May 2020

Accepted 22 May 2020

Published Online First

3 July 2020

Check for updates

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Lyckhage LF, Hansen ML, Toft JC, et al. *Heart* 2021;**107**:635–641.

ABSTRACT

Background and purpose The diagnostic benefit of using continuous ECG (cECG) for poststroke atrial fibrillation (AF) screening in a primary care setting is unclear. We aimed to assess the diagnostic yield from screening patients who previously had a stroke with a 7-day Holter monitor.

Methods Patients older than 49 years, naive to AF, with an ischaemic stroke over 1 year before enrolment were included. In a primary care setting, all patients were screened for AF using pulse palpation, 12-lead ECG and 7-day Holter monitoring. Further, NT-proBNP was determined at baseline.

Results 7-day Holter monitoring uncovered AF in 17 of 366 patients (4.6% (95% CI 2.7 to 7.3)). The number needed to screen was 22 patients (14–37). 12-lead ECG uncovered AF in 3 patients (0.82% (95% CI 0.17 to 2.4)), and 122 patients had irregular pulse during pulse palpation (33.5% (95% CI 28.7 to 38.2)). When using 7-day Holter monitoring as reference standard, the sensitivity of pulse palpation and 12-lead ECG was 47% (95% CI 23% to 72%) and 18% (95% CI 4% to 43%). High levels (≥ 400 pg/mL) of NT-proBNP versus low levels (≤ 200 pg/mL) were not associated with AF in the univariate analysis nor when adjusted for age (OR 2.4 (95% CI 0.5 to 8.4) and 1.6 (95% CI 0.3 to 6.0)).

Conclusions A relevant proportion of patients with stroke more than 1 year before inclusion were diagnosed with AF through 7-day Holter monitoring. Given the low sensitivities of pulse palpation and 12-lead ECG, additional cECG may be considered during poststroke primary care follow-up.

INTRODUCTION

Ischaemic stroke is a prevalent and potentially debilitating condition, where identification and treatment of potential risk factors of recurrent stroke are crucial.¹ Atrial fibrillation (AF) is one of the most important risk factors² and is associated with a five-fold increased risk of ischemic stroke.² This risk is reducible by converting therapy from antiplatelet to oral anticoagulant treatment (OAC).³ Effective AF detection after stroke is challenging since AF is often paroxysmal and asymptomatic.⁴ Randomised clinical trials and meta-analyses have shown that increasing the time of ECG monitoring in the early phase after ischaemic stroke uncovers progressively more AF.^{5–7} Consequently, current recommendations include use of continuous ECG (cECG) early after ischaemic stroke.⁸

The long-term efforts to prevent recurrent stroke are typically handled at patients' general practice (GP) clinic. Guidelines for the elderly population include opportunistic pulse palpation followed by 12-lead ECG in case of irregular pulse.⁸ Nevertheless, there are currently no guidelines specific to primary care poststroke AF screening. Brachmann *et al*⁶ showed that monitoring patients with cryptogenic stroke with implantable loop recorder detected AF in 30% after 3 years compared with 12.4% after 1 year. Thus, AF could be markedly underdiagnosed even years after stroke without the use of effective systematic screening methods. Using implantable loop recorders in all patients who had a stroke does, however, seem unrealistic.

This is the first study to investigate the role of external cECG as an AF screening tool in a primary care setting beyond the first year after ischaemic stroke. In collaboration with GP clinics, our primary aim was to determine the proportion of newly diagnosed AF by use of 7-day Holter monitoring. The secondary aims included assessment of the sensitivity of pulse palpation and 12-lead ECG, using 7-day Holter monitoring as a reference standard, and assessment of the association of high versus low levels of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) with the risk of AF.

METHODS

Design, setting and data collection

This prospective cohort study was a collaboration between the Neurovascular Center, Zealand University Hospital (NVC) and two GP clinics in the Region of Zealand, Denmark (Borup and Havdrup). Patient recruitment began in November 2016 at Borup GP clinic and in November 2017 at Havdrup GP clinic. We initially aimed to conduct all recruitment and data collection via the primary sector. Through a protocol amendment in March 2018, we improved recruitment rate by expanding the source population to all participants previously admitted to the NVC and set up facilities for data collection at the latter. Due to changes in the hospital patient record systems, data were not available for participants with stroke beyond 10 years. Consequently, we restricted time since last stroke to 1–10 years prior to inclusion for all participants, meaning some of the participants recruited via the GP clinic in Borup were excluded from analysis. Enrolment was completed in April 2019. Trained GP nurses conducted data collection in the primary sector and

research assistants or the primary investigator conducted data collection at the NVC.

Study participants

Participants included were AF-naïve, had ischaemic stroke over 1 year before enrolment and were older than 49 at stroke onset. Participants with a systemic infection or taking antiarrhythmic drugs (class I and III, digoxin, flecainide, and non-dihydropyridine calcium-channel blockers), who had cECG within 1 year before inclusion, and who had an implanted loop recorder, cardioverter defibrillator or pacemaker were not eligible. Participants with an acute infection or surgery were included at least 1 month after remission. Participants taking OAC for other indications than AF were included.

The ischaemic stroke diagnosis, established through review of patient records, was defined as evidence of previous focal central nervous system (CNS) infarction documented by clinical findings and/or acute or chronic infarction, or a relevant perfusion defect on CT or MRI.⁹ Only imaging related to the last stroke diagnosis was evaluated. Where imaging lacked evidence of infarction, we required neurological findings consistent with upper motor neuron lesions, such as pathological reflexes, upper extremity pronation, central facial palsy or central ophthalmoplegia, and no probable differential diagnosis. We also included participants with silent CNS infarction, detected during evaluation without certain stroke symptoms. Silent CNS infarctions are associated with increased risk of stroke.¹⁰ The subtype classification of stroke was done in accordance with the Trial of Org 10172 in Acute Stroke Treatment.¹¹

Cardiac rhythm evaluation

Study evaluation for AF or atrial flutter included pulse palpation for irregular pulse, 12-lead ECG and 7-day cECG monitoring. All three evaluations were performed on all participants and 12-lead ECG was performed minutes before or after application of Holter equipment. Radial artery pulse palpation for pulse irregularity was done for a minimum of 20 s or as long as needed.¹² The sensitivity and specificity of pulse palpation were 0.92% and 0.82% in previous studies.¹³ A two-channel 7-day Holter monitoring was conducted using the Lifecard CF (Spacelabs Healthcare, Snoqualmie, Washington, USA). The Pathfinder SL software was used for subsequent automatic AF screening and has shown a sensitivity and specificity of over 98% and 80%, respectively.¹⁴ The algorithm for AF detection was described by Haeblerin *et al.*¹⁴ To confirm the diagnosis, all detected episodes were adjudicated by the primary investigator and two specialist raters. A third specialist rater determined the diagnosis in cases of inter-rater disagreement. AF was defined according to accepted convention as at least 30 s of absolutely irregular RR intervals and the absence of p-waves.⁸ Due to a regional technical error, the raw Holter ECG data are unavailable, but ECG segments of all episodes of confirmed or suspected episodes of AF are saved and stored as separate PDF files.

NT-proBNP and further covariates are described in online supplementary appendix methods and table S1, respectively.

Statistical analysis

The sample size of 400 participants was obtained for Clopper-Pearson CI for binomial proportion. A statistician at the department of 'Production, Research & Innovation (PFI)' in the 'Region of Zealand' conducted the sample size calculation. The online supplementary appendix describes in detail the methods used for our power calculation.

Figure 1 Flow chart of patient selection and distribution between study locations. *Class I and III, digoxin, flecainide, and non-dihydropyridine calcium-channel blockers. GP clinic, general practice clinic; ICD, implantable cardioverter defibrillator; TIA, transient ischaemic attack.

Baseline statistics of categorical variables were expressed as counts and percentages. Normally and non-normally distributed continuous variables were expressed as a median with limits of IQR (Q1–Q3) and as mean and SD. The Clopper-Pearson interval method was used to determine percentages of AF (including 95% CI) as diagnosed by 12-lead ECG, 7-day Holter monitoring and for participants with irregular pulse determined during pulse palpation. Sensitivity, specificity, and positive and negative predictive values including exact binomial confidence intervals were calculated by the *epi.test* function in the *epiR* package in RStudio. Further, the OR of AF in high versus low levels of NT-proBNP was assessed by univariable logistic regression analysis and adjusted for age. Exploratory univariable analysis for AF risk by each covariable was conducted (online supplementary appendix methods and table S2). RStudio V.1.1.453 was used for statistical analyses.

All participants gave an informed written consent.

RESULTS

Study population

Of 1424 participants eligible for inclusion, 418 (29.4%) accepted study participation. Of these, the first 400 were enrolled. There was no significant difference in age and sex distribution between participants and non-participants (online supplementary appendix table S3). After excluding 34 participants, the study population consisted of 366 participants. Twenty-two participants were included solely based on a chronic cerebral infarct. Figure 1 illustrates the selection of participants.

Baseline characteristics

The mean age was 70 years (SD 8) and 65.6% of the participants were men. The median time from last stroke was 3.9 years (Q1–Q3 2.5–5.9) and the median CHA₂DS₂-VASc score (Congestive heart failure, Hypertension, Age, Diabetes, previous Stroke/transient ischemic attack, Vascular disease, Sex category) was 4 (Q1–Q3 4–5). No participants had mitral valve stenosis or a mechanical heart valve. Table 1 shows the baseline characteristics.

AF yield

Pulse palpation, 12-lead ECG and 7-day Holter monitoring were conducted on all participants and the median duration

Table 1 Baseline characteristics

	All, N=366	No atrial fibrillation, n=349	Atrial fibrillation, n=17
Age, mean (SD)	70 (8.1)	69.8 (8)	74.6 (9.3)
Age ≥75 years	106 (29)	97 (27.8)	9 (52.9)
Female	126 (34.4)	124 (35.5)	2 (11.8)
Years since last stroke	3.9 (2.5–5.9)	3.9 (2.5–5.9)	3.8 (2.4–4.6)
>1 clinical stroke or TIA	104 (28.4)	101 (28.9)	3 (17.6)
CHA ₂ DS ₂ -VASc score	4 (4–5)	4 (4–5)	5 (4–6)
CHA ₂ DS ₂ -VASc groups			
2–3	83 (22.7)	81 (23.2)	2 (11.8)
4–5	230 (62.8)	220 (63)	10 (58.8)
6–7	53 (14.5)	48 (13.8)	5 (29.4)
Comorbidities			
Ischaemic heart disease	27 (7.4)	25 (7.2)	2 (11.8)
Heart failure	1 (0.3)	1 (0.3)	0
Hypertension	255 (69.7)	241 (69.1)	14 (82.4)
Diabetes	50 (13.7)	46 (13.2)	4 (23.5)
COPD	17 (4.6)	16 (4.6)	1 (5.9)
Kidney disease	13 (3.6)	12 (3.4)	1 (5.9)
Sleep apnoea	17 (4.6)	16 (4.6)	1 (5.9)
Smoking (pack years)			
None	118 (32.2)	111 (31.8)	7 (41.2)
1–20	76 (20.8)	72 (20.6)	4 (23.5)
>20	172 (47)	166 (47.6)	6 (35.3)
Excessive alcohol intake	44 (12)	42 (12)	2 (11.8)
Married/partner	269 (73.5)	255 (73.1)	14 (82.4)
Nursing home	1 (0.3)	1 (0.3)	0
No acute infarct on imaging	163 (44.5)	158 (45.3)	5 (29.4)
Acute lacunar infarct	87 (23.8)	87 (24.9)	0
Acute non-lacunar infarct	91 (24.9)	81 (23.2)	10 (58.8)
Ultrasound or angiography conducted	322 (88)	308 (88.3)	14 (82.4)
Occlusion or stenosis*	70 (19.1)	65 (18.6)	5 (29.4)
Prior cECG	148 (40.4)	140 (40.1)	8 (47.1)
Chronic infarction	180 (49.2)	174 (49.9)	6 (35.3)
TOAST classification			
Small artery occlusion	169 (46.2)	165 (47.3)	4 (23.5)
Cardioembolism	0	0	0
Large-artery atherosclerosis	43 (11.7)	39 (11.2)	4 (23.5)
Undetermined	149 (40.7)	140 (40.1)	9 (52.9)
Other†	5 (1.4)	5 (1.4)	0
Pulse	70 (62–78)	70 (62–78)	68 (61–75)
Systolic BP	141.5 (131–153)	142 (131–153)	137 (132–153)
Diastolic BP	83 (77–92)	84 (77–92)	82 (70–87)
BMI (kg/m ²)	26.9 (24.2–29.9)	26.8 (24.1–30)	28.2 (26.7–29)
LDL-C (mmol/L)	1.8 (1.4–2.3)	1.8 (1.4–2.3)	2 (1.3–2.2)
Dyslipidaemia (LDL >1.8 mmol/L)	176 (48.1)	165 (47.3)	11 (64.7)
Creatinine (μmol/L)	79 (67–92)	78 (66–92)	85 (75–96)
HbA1C (mmol/mol)	38 (36–41)	38 (36–41)	40 (37–42)
NT-proBNP (pg/mL)	105.3 (51.2–211.4)	101.5 (48.2–208)	191.1 (92.2–339.1)
NT-proBNP ≤200 pg/mL	267 (73)	258 (73.9)	9 (52.9)
NT-proBNP 199–399 pg/mL	39 (10.7)	36 (10.3)	3 (17.6)
NT-proBNP ≥400 pg/mL	60 (16.4)	55 (15.8)	5 (29.4)

All categorical data are expressed as n (%).

The variables years since last stroke, CHA₂DS₂-VASc score, pulse, BP, BMI, LDL-C, creatinine, HbA1C and NT-proBNP are expressed with median (Q1–Q3).

*>50% occlusion or stenosis.

†Vascular dissection and in one patient vasculitis was suspected.

BMI, body mass index; BP, blood pressure; cECG, continuous ECG; CHA₂DS₂-VASc, Congestive heart failure, Hypertension, Age, Diabetes, previous Stroke/transient ischemic attack, Vascular disease, Sex category; COPD, chronic obstructive pulmonary disorder; HbA1C, haemoglobin A1C; LDL-C, low-density lipoprotein cholesterol; NT-ProBNP, N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP); TIA, transient ischaemic attack; TOAST, Trial of Org 10 172 in Acute Stroke Treatment.

Figure 2 Distribution of the total burden of AF during 7-day Holter monitoring in participants with ischaemic stroke more than 1 year before inclusion. Displayed with absolute values (A) and proportion of readable Holter ECG (B). AF, atrial fibrillation.

of interpretable Holter data was 6.9 days (Q1–Q3 6.8–7.0). Online supplementary appendix table S4 depicts the distribution of completed Holter durations. Of the participants, >93% completed more than 6 days of Holter monitoring. Pulse palpation revealed irregular pulse in 122 of 366 participants (33% (95% CI 28.5 to 38.4)). The 12-lead ECG showed AF in 3 of 366 participants (0.82% (95% CI 0.17 to 2.4)), and after 7-day Holter monitoring AF was detected in 17 of 366 participants (4.6% (95% CI 2.7 to 7.3)). The number needed to screen with 7-day Holter monitoring was 22 (14–37). Since no AF detected by 12-lead ECG was missed during 7-day Holter monitoring, the proportion of AF uncovered by the complete evaluation was equivalent to the proportion achieved by Holter monitoring. Figure 2 depicts the distributions of the time in AF during Holter monitoring. Absolute values and proportions are displayed in online supplementary appendix table S5. Most participants had AF for less than 1% of the time (10 of 17 AF cases).

Pulse palpation and 12-lead ECG

Table 2 is a 2×2 contingency table outlining the distribution of outcomes between evaluation methods. Using 7-day Holter monitoring as a reference standard, pulse palpation missed 9 of 17 participants with AF. The 12-lead ECG missed 14 of 17 participants with AF. The sensitivity of pulse palpation was 47% (95% CI 23% to 72%) and the sensitivity of 12-lead ECG was 18% (95% CI 4% to 43%) (table 3).

Table 2 Contingency table illustrating the distribution of outcomes

7-day Holter monitoring		
Pulse palpation	+AF	–AF
Pulse irregular	8	114
Pulse regular	9	235
7-day Holter monitoring		
12-lead ECG	+AF	–AF
AF	3	0
Sinus rhythm	14	349
12-lead ECG		
Pulse palpation	+AF	–AF
Pulse irregular	2	120
Pulse regular	1	243

AF, atrial fibrillation.

Table 3 Proportions of detected AF and sensitivity, specificity, PPV and NPV for detecting AF by pulse palpation and 12-lead ECG holding 7-day Holter monitoring as a reference standard

	Accuracy in % (95% CI)			
	Sensitivity	Specificity	PPV	NPV
Pulse irregular	47 (23 to 72)	67 (62 to 72)	7 (3 to 13)	96 (93 to 98)
12-lead ECG	18 (4 to 43)	100 (99 to 100)*	100 (30 to 100)	96 (94 to 98)
7-day Holter monitoring	Reference standard			

*One-sided 97.5% CI.

AF, atrial fibrillation; NPV, negative predictive value; PPV, positive predictive value.

Clinical factors associated with AF

Increasing age was associated with increased odds of AF (OR=1.1, 95% CI (1.02 to 1.15)). There was no significant increase in the odds of AF for participants with high levels of NT-proBNP (≥ 400 pg/mL) compared with lower levels (≤ 200 pg/mL), and neither in the univariate analysis nor when adjusting for age (OR 2.4 (95% CI 0.5 to 8.4) and 1.6 (95% CI 0.3 to 6.0)). There was no significant difference in the time passed since stroke between participants with and without AF (online supplementary appendix table S2).

None of the participants with AF had a secondary precipitant (infection, anaemia, thyroid disease, recent surgery). At baseline 58% of participants (n=222) reported cardiopulmonary symptoms experienced at least within the last 3 months prior to inclusion. Cardiopulmonary symptoms were not associated with increased odds of AF (online supplementary appendix table S6).

In a sensitivity analysis we added participants excluded due to transient ischaemic attack or stroke over 10 years prior to our population. The proportion of participants with AF in this population was 4.4% (95% CI 2.6 to 7.0). The remaining analyses remained robust.

DISCUSSION

Screening patients in a primary care setting over 1 year post-stroke using 7-day Holter monitoring uncovered AF in 4.6% of participants without known AF. Compared with 7-day Holter monitoring, more than half of AF diagnoses were undetectable with pulse palpation and more than 82.3% were missed by 12-lead ECG. High versus low levels of NT-proBNP were not significantly associated with AF. Without the use of cECG, in addition to opportunistic pulse palpation and routine 12-lead ECG, a considerable number of patients with AF may be underdiagnosed during routine poststroke AF screening in the primary sector.

Previous studies cECG and AF yield

Previous studies of poststroke AF detection focused on the period immediately after stroke. A meta-analysis including 31 studies estimated an expected AF detection rate by 7-day monitoring of 8.9%.¹⁵ Similarly, 10-day Holter monitoring identified AF in 9% in the Find-AF(RANDOMISED) trial.⁷ The comparatively lower detection rate found in our study may be explained by a time-related dilution of participants with AF for several reasons. First is the exclusion of participants diagnosed with AF before inclusion. Second is the attrition of participants with undiagnosed AF due to the high risk of a recurrent stroke and death.^{2,16} Third, AF is associated with more severe strokes¹⁷ and therefore such patients more often reside at a nursing home. Due to practical issues, only patients living in their own home were

approached for participation in this study. Further, study participation required the ability to understand and cooperate during the study. Consequently, the results of this study may reflect a subset of patients who had a stroke with lower comorbid burden and less severe strokes.

Pulse palpation and 12-lead ECG versus cECG

Irregular pulse felt during pulse palpation could be attributed to non-AF arrhythmias such as frequent atrial or ventricular ectopy or sinus arrhythmia. The sensitivity and specificity of pulse palpation were higher in previous studies (92% and 82%) than in the present study (47% and 68.2%).¹³ This could be explained by the use of 12-lead ECG as a reference standard instead of continuous monitoring.

The AF yield achieved by 12-lead ECG in this study (0.82% (95% CI 0.17 to 2.4)) was in line with previous studies. A meta-analysis and a large Danish observational multicentre study investigated primary care screening of participants 65 years or older, whereof 5%–7% previously had a stroke.^{18 19} AF was uncovered in 1%–1.4% of the screened.^{18 19} The study population was younger in our study, but having a previous stroke is a likely marker of increased risk of AF.²⁰ Our study showed a substantially increased AF detection with cECG compared with 12-lead ECG. Studies involving primary care screening of non-stroke patients have shown similar results. The STROKESTOP study screened Swedish residents aged 75–76 years old with repeated thumb placement on a handheld ECG for 2 weeks.²¹ AF was uncovered in 3%, a fourfold increase compared with baseline 12-lead ECG. Further, the addition of cECG to 12-lead ECG after acute stroke has proved beneficial in various studies; however, studies differ in terms of age, stroke subtype and cECG monitoring length and methods.⁵

NT-proBNP and AF

Opposed to findings in previous studies, our study showed that increased NT-proBNP levels did not seem useful as a selection parameter for extended AF screening.²² The optimal cut-off value differed across these studies, but even a comparison of assumed low and high risk values as previously suggested²³ showed no significant association to AF in the present study. A lack of power for this secondary endpoint may explain our finding.

Relation between AF and prior stroke

The time passed since ischaemic stroke was several years for most participants, why all AF cases may not be causally linked to the index stroke. AF is associated with large vessel embolic occlusions²⁴ and a causal link is supported by the presence of an acute non-lacunar infarct on cerebral imaging in all participants diagnosed with AF where an acute infarct was documented. Further, a low AF burden and a considerable proportion of participants with cryptogenic stroke (40.7%) might suggest the presence of an ‘embolic stroke of undetermined source’, such as AF, which is described by Hart *et al.*²⁵ AF could have been coexisting because risk factors of AF and stroke overlap.^{26 27} Further, Kamel *et al.*²⁸ described an ‘atrial substrate model’ in which atrial myopathy may create an atrial substrate with independent thromboembolic qualities. This means the presence of an atrial substrate may cause stroke without the presence of AF. AF may in turn be a ‘lagging marker of thrombotic atrial abnormalities’.²⁸ Additionally, the low AF burden detected in our study could be indicative of a relatively recently developed AF. Although speculative, the atrial substrate model therefore seems to explain both why

all participants with AF had non-lacunar strokes and it accounts for the long time passed between index stroke and AF.²⁸

Clinical implications

Following current guidelines, ischaemic strokes yield two points on the CHA₂DS₂-VASc scale, and a shift from antiplatelet to OAC treatment is recommended independently of causal connection.⁸ However, the necessary AF duration and burden associated with a prognostic benefit of OAC are unknown, and more patients with low burden AF will be caught using continuous monitoring compared with using 12-lead ECG. A low AF burden has been associated with a lower stroke recurrence risk than high burden AF.²⁹ Consequently, one may question the prognostic benefits of more aggressive systematic screening during poststroke primary care follow-up. On the other side, AF is considered a progressive disease, deteriorating with age and comorbid burden.⁸ Further, cECG is still a snap shot of a relatively short time window, leaving us unable to determine the true AF burden over a longer time period. These factors and a high stroke recurrence risk and mortality in untreated AF^{2 16} support a need to improve AF detection even long after stroke.

There is currently no evidence that intensive AF screening is independently associated with a reduction in stroke recurrence and mortality. Ongoing studies including patients who had acute stroke aim to clarify this question.³⁰

Limitations and strengths

A high proportion of participants complained of cardiopulmonary symptoms, but these were not associated with increased odds of AF. There was no control group, which is why we cannot preclude that the participants would have been diagnosed later without our interference. There is therefore a

Key messages

What is already known on this subject?

- Uncovering atrial fibrillation after stroke is imperative because a shift to oral anticoagulant treatment effectively reduces stroke recurrence and mortality.
- Atrial fibrillation often remains undiagnosed, but use of continuous ECG after acute stroke is superior to single-point ECG evaluations.
- There are no guidelines on atrial fibrillation detection long after stroke and no studies have investigated the diagnostic value of using continuous ECG for poststroke screening in primary care.

What might this study add?

- Using 7-day Holter monitoring in participants with stroke over 1 year before inclusion, in a primary care setting, revealed new-onset atrial fibrillation in a relevant proportion of participants.
- 7-day Holter monitoring substantially improved the detection rate compared with baseline pulse palpation and 12-lead ECG.

How might this impact on clinical practice?

- The results suggest that continuous ECG methods should be considered for poststroke atrial fibrillation screening even long after stroke.
- They further question the lack of guidelines for atrial fibrillation screening during poststroke primary care.

risk of selection bias, affecting external validity. A subset of participants had a chronic infarct on imaging without certain clinical evidence of recent stroke. This limits the possibility of assessing time lag since last stroke, which may have been underestimated. Further, the risk of AF may be different in these participants compared with participants with clinical infarcts, potentially diluting our results. Our study is strengthened by a large sample size and a low dropout rate. Further, the heterogeneity of stroke subtypes mimics conditions in real life, thereby increasing generalisability.

CONCLUSIONS

We showed that 7-day Holter monitoring for poststroke AF detection in a primary care setting uncovered a relevant number of AF cases and substantially improved the detection rate compared with pulse palpation and 12-lead ECG. Therefore, cECG seems relevant not only for AF detection in the acute phase after ischaemic stroke, but also as an additional tool for AF screening in GP clinics long after stroke. Further studies investigating primary sector AF screening long after stroke would be needed to clarify the prognostic impact, the benefit and feasibility of different cECG devices, and to identify which markers of AF could be used as a selection tool for extended screening.

Acknowledgements We thank all those who participated in this study or who expressed interest in participating. We also thank the research assistants and the staff at the Department of Neurology Zealand University Hospital and all staff at both GP clinics for the collaboration. We in particular thank Hanne Bjørnum (RN), Karen Larsen (RN), Thomas Andersen (GP) and research assistant Julie Kasten Rønne for all their important help in the data collection process. Thomas Andersen and the Department of Neurology provided resources and facilities for participant recruitment and analysis. At Borup GP clinic Hanne Bjørnum recruited the participants, managed the logistics, carried out the data collection and supervised the training of other data collectors. Karen Larsen and Julie Kasten Rønne collected the data at Havdrup GP clinic NVC, respectively.

Contributors JCT, SLL and TW formulated the idea. LFL drafted the protocol, designed the study, recruited the patients, collected the data, analysed the data and drafted the manuscript. TW provided critical review of the protocol. SLL provided resources and facilities for participant recruitment and analysis. LFL analysed the ECG data, and AMA, MLH and BB provided critical reviews of ECG events. JCT was consulted for clinical cardiac questions during the study. TW and LFL acquired financial support. TW and MLH supervised the research activities. All authors critically revised and approved the final version of the manuscript.

Funding The study was supported by Bayer, Boehringer Ingelheim, the Department of Neurology, Zealand University Hospital, 'Region Sjællands Ordinære pulje', 'Grosserer L.F. Foghts Fond', 'A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal-Fonden til Lægevidenskabens Fremme' and 'Hans og Nora Buchards Fond'. The sponsors had no role in the conception, drafting the protocol, conducting the analyses or interpreting the results.

Competing interests LFL has competing interests as stated under the Funding section and personal fees from Bayer, outside the submitted work. TW reports personal fees from Boehringer Ingelheim and Bayer, outside the submitted work. MLH, JCT, SLL, BB and AMA have no disclosures.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The study was conducted in accordance with the Declaration of Helsinki. The Region Zealand Committee of Health Research Ethics and the Danish Data Protection Agency approved the protocol.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Anonymised data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is

properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Louise Feldborg Lyckhage <http://orcid.org/0000-0003-4866-1169>

REFERENCES

- Benjamin EJ, Muntner P, Alonso A, *et al.* Heart disease and stroke Statistics-2019 update: a report from the American heart association. *Circulation* 2019;139:e56–28.
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. *Stroke* 1991;22:983–8.
- Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 2007;146:857–67.
- Healey JS, Connolly SJ, Gold MR, *et al.* Subclinical atrial fibrillation and the risk of stroke. *N Engl J Med* 2012;366:120–9.
- Sposato LA, Cipriano LE, Saposnik G, *et al.* Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol* 2015;14:377–87.
- Brachmann J, Morillo CA, Sanna T, *et al.* Uncovering atrial fibrillation beyond short-term monitoring in cryptogenic stroke patients: three-year results from the cryptogenic stroke and underlying atrial fibrillation trial. *Circ Arrhythm Electrophysiol* 2016;9:e003333.
- Wachter R, Gröschel K, Gelbrich G, *et al.* Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-^{RANDOMISED}AF): an open-label controlled trial. *Lancet Neurol* 2017;16:282–90.
- Kirchhof P, Benussi S, Kotecha D, *et al.* 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). *Eur Heart J* 2016;ehw210.
- Sacco RL, Kasner SE, Broderick JP, *et al.* An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American heart Association/American stroke association. *Stroke* 2013;44:2064–89.
- Smith EE, Saposnik G, Biessels GJ, *et al.* Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American heart Association/American stroke association. *Stroke* 2017;48:e44–71.
- Adams HP, Bendixen BH, Kappelle LJ, *et al.* Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. TOAST. trial of ORG 10172 in acute stroke treatment. *Stroke* 1993;24:35–41.
- Morgan S, Mant D. Randomised trial of two approaches to screening for atrial fibrillation in UK general practice. *Br J Gen Pract* 2002;52:377–80.
- Taggar JS, Coleman T, Lewis S, *et al.* Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: a systematic review and meta-analysis. *Eur J Prev Cardiol* 2016;23:1330–8.
- Haeberlin A, Roten L, Schilling M, *et al.* Software-based detection of atrial fibrillation in long-term ECGs. *Heart Rhythm* 2014;11:933–8.
- Dussault C, Toeg H, Nathan M, *et al.* Electrocardiographic monitoring for detecting atrial fibrillation after ischemic stroke or transient ischemic attack: systematic review and meta-analysis. *Circ Arrhythm Electrophysiol* 2015;8:263–9.
- Benjamin EJ, Wolf PA, D'Agostino RB, *et al.* Impact of atrial fibrillation on the risk of death: the Framingham heart study. *Circulation* 1998;98:946–52.
- Lin HJ, Wolf PA, Kelly-Hayes M, *et al.* Stroke severity in atrial fibrillation. The Framingham study. *Stroke* 1996;27:1760–4.
- Lowres N, Neubeck L, Redfern J, *et al.* Screening to identify unknown atrial fibrillation. A systematic review. *Thromb Haemostasis* 2013;110:213–22.
- Hald J, Poulsen PB, Qvist I, *et al.* Opportunistic screening for atrial fibrillation in a real-life setting in general practice in Denmark-The atrial fibrillation found on routine detection (afford) non-interventional study. *PLoS One* 2017;12:e0188086.
- Fauchier L, Clementy N, Pelade C, *et al.* Patients with ischemic stroke and incident atrial fibrillation: a nationwide cohort study. *Stroke* 2015;46:2432–7.
- Svennberg E, Engdahl J, Al-Khalili F, *et al.* Mass screening for untreated atrial fibrillation: the STROKESTOP study. *Circulation* 2015;131:2176–84.
- Sepehri Shamloo A, Bollmann A, Dargatzis N, *et al.* Natriuretic peptides: biomarkers for atrial fibrillation management. *Clin Res Cardiol* 2020;33:1–3.
- Haeusler KG, Gröschel K, Köhrmann M, *et al.* Expert opinion paper on atrial fibrillation detection after ischemic stroke. *Clin Res Cardiol* 2018;107:871–80.
- Bang OY, Ovbiagele B, Kim JS. Evaluation of cryptogenic stroke with advanced diagnostic techniques. *Stroke* 2014;45:1186–94.
- Hart RG, Diener H-C, Coutts SB, *et al.* Embolic strokes of undetermined source: the case for a new clinical construct. *Lancet Neurol* 2014;13:429–38.

- 26 Andrade J, Khairy P, Dobrev D, *et al*. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. *Circ Res* 2014;114:1453–68.
- 27 Guzik A, Bushnell C. Stroke epidemiology and risk factor management. *Continuum* 2017;23:15–39.
- 28 Kamel H, Okin PM, Elkind MSV, *et al*. Atrial fibrillation and mechanisms of stroke: time for a new model. *Stroke* 2016;47:895–900.
- 29 Go AS, Reynolds K, Yang J, *et al*. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM study. *JAMA Cardiol* 2018;3:601–8.
- 30 Haeusler KG, Kirchhof P, Heuschmann PU, *et al*. Impact of standardized monitoring for detection of atrial fibrillation in ischemic stroke (MonDAFIS): rationale and design of a prospective randomized multicenter study. *Am Heart J* 2016;172:19–25.